{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:00:53Z","timestamp":1791219653488,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["NIHR305609"],"award-info":[{"award-number":["NIHR305609"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-operative management after total neoadjuvant therapy (TNT) has emerged as a potential strategy for patients with locally advanced rectal cancer (LARC) achieving clinical complete response (cCR). Circulating tumour DNA (ctDNA) has been proposed as a systemic biomarker to augment response assessment, but its role in predicting cCR and local regrowth remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were performed of studies evaluating ctDNA dynamics in patients with LARC undergoing TNT. PubMed, EMBASE, and Web of Science databases were searched from database inception to 31 March 2026. Primary outcomes were the association between post-TNT ctDNA status and cCR and sustained cCR. Pooled odds ratios (ORs) were calculated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies comprising 597 patients were included. ctDNA negativity following TNT was associated with higher likelihood of cCR (OR 8.01; 95% confidence interval (c.i.) 1.43 to 44.90; I2 = 27.0%). The association with sustained cCR was not statistically significant (OR 3.46; 95% c.i. 0.03 to 394.64; I2 = 59.9%). Across studies, post-TNT ctDNA positivity was associated with inferior disease-free, distant recurrence-free, and progression-free survival. ctDNA demonstrated high specificity and positive predictive value for residual disease, but low sensitivity for the detection of residual local disease and local regrowth, with a substantial proportion of patients with residual tumour remaining ctDNA negative at restaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Post-TNT ctDNA positivity may identify patients at increased risk of adverse oncological outcomes. However, ctDNA negativity was not consistently associated with the absence of residual local disease, limiting its utility as an independent determinant of organ preservation eligibility. ctDNA should be interpreted as a complementary tool for systemic risk stratification alongside established anatomical assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjsopen\/zrag142","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:20:59Z","timestamp":1785151259000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of circulating tumour DNA in predicting complete clinical response and local regrowth after total neoadjuvant therapy for rectal cancer: meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6889-3496","authenticated-orcid":false,"given":"Nikhil","family":"Lal","sequence":"first","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London , London ,","place":["UK"]},{"name":"Complex Cancer Clinic, St Mark\u2019s the National Bowel Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Royal Berkshire NHS Foundation Trust , Reading ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Hodges","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London , London ,","place":["UK"]},{"name":"Complex Cancer Clinic, St Mark\u2019s the National Bowel Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London , London ,","place":["UK"]},{"name":"Complex Cancer Clinic, St Mark\u2019s the National Bowel Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100512370859700_zrag142-B1","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.14309\/ajg.0000000000003460","article-title":"Incidence and survival of colorectal cancer in the United Kingdom from 2000 to 2021: a population-based cohort study.","volume":"120","author":"Pedregal-Pascual","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026100512370859700_zrag142-B2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"key":"2026100512370859700_zrag142-B3","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"2026100512370859700_zrag142-B4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/014107688808100904","article-title":"The \u2018holy plane\u2019 of rectal surgery","volume":"81","author":"Heald","year":"1988","journal-title":"J R Soc Med"},{"key":"2026100512370859700_zrag142-B5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer.","volume":"11","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026100512370859700_zrag142-B6","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100512370859700_zrag142-B7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100512370859700_zrag142-B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026100512370859700_zrag142-B9","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100512370859700_zrag142-B10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026100512370859700_zrag142-B11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026100512370859700_zrag142-B12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(25)00542-X","article-title":"Total neoadjuvant therapy followed by non-operative management or surgery in stage II\u2013III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial.","volume":"26","author":"Amatu","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026100512370859700_zrag142-B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13244-019-0706-x","article-title":"Response evaluation after neoadjuvant treatment for rectal cancer using modern MR imaging: a pictorial review","volume":"10","author":"Lambregts","year":"2019","journal-title":"Insights Imaging"},{"key":"2026100512370859700_zrag142-B14","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.949300","article-title":"A review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response","volume":"31","author":"Parums","year":"2025","journal-title":"Med Sci Monit"},{"key":"2026100512370859700_zrag142-B15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2026100512370859700_zrag142-B16","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/cancers17152560","article-title":"Circulating tumor DNA detects minimal residual disease in patients with locally advanced rectal cancer after total neoadjuvant therapy","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026100512370859700_zrag142-B17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-20-2299","article-title":"Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study.","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026100512370859700_zrag142-B18","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.3390\/cancers16244173","article-title":"Circulating tumor DNA for prediction of complete pathological response to neoadjuvant radiochemotherapy in locally advanced rectal cancer (NEORECT trial)","volume":"16","author":"Mogele","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026100512370859700_zrag142-B19","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026100512370859700_zrag142-B20","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026100512370859700_zrag142-B21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/DCR.0000000000003950","article-title":"Brave new world: analysis of early clinical experience with molecular sequencing in the treatment of rectal cancer","volume":"68","author":"Yee","year":"2025","journal-title":"Dis Colon Rectum"},{"key":"2026100512370859700_zrag142-B22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41698-025-01208-w","article-title":"Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer.","volume":"10","author":"Manca","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026100512370859700_zrag142-B23","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-25-1242","article-title":"ctDNA longitudinal analysis during total neoadjuvant therapy and nonoperative management for locally advanced rectal cancer: a biomarker study from the NOMINATE trial.","volume":"31","author":"Akiyoshi","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026100512370859700_zrag142-B24","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1093\/oncolo\/oyad336","article-title":"Circulating tumor DNA to predict radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer","volume":"29","author":"Alden","year":"2024","journal-title":"Oncologist"},{"key":"2026100512370859700_zrag142-B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103945","article-title":"Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA","volume":"78","author":"Liu","year":"2022","journal-title":"eBioMedicine"},{"key":"2026100512370859700_zrag142-B26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-19-1996","article-title":"MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer.","volume":"26","author":"Khakoo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026100512370859700_zrag142-B27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026100512370859700_zrag142-B28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026100512370859700_zrag142-B29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2026100512370859700_zrag142-B30","article-title":"Deep learning and radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer.","volume":"8","author":"Bibault","year":"2018","journal-title":"Sci Rep"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/5\/zrag142\/71605542\/zrag142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/5\/zrag142\/71605542\/zrag142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:37:15Z","timestamp":1791218235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrag142\/8865186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrag142","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,4]]},"article-number":"zrag142"}}